Articles by Jo Watts - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jo Watts

Live Report From ACHEMA

Jun 21, 2012

With ACHEMA entering its penultimate day and many visitors preparing to return home after a busy stay in Frankfurt, PTE editor Jo Watts gives her closing thoughts on the show.

Day Two at ACHEMA

Jun 20, 2012

The majority of the PTE team is in attendance at ACHEMA. Dr Jo Watts gives us a live update from day two of the show.

Live: ACHEMA Opening Day Report

Jun 19, 2012

The majority of the PTE team is in attendance at ACHEMA. Our editor, Dr Jo Watts, gives her opinion on how the first day of the show went and what her expectations are for the rest of the week.

EMA Opens Biosimilars Guidelines for Comments

Jun 8, 2012

Updated European guideline provides more detail on quality issues surrounding biosimilar medicines.

EMA Pharmacovigilance Legislation to Take Effect; New Q&A Document Offers Practical Guidance to Industry

Jun 6, 2012

In July 2012, new pharmacovigilance legislation will come into effect across the EU as a result of changes adopted in 2010, specifically EU Regulation No. 1235 and Directive 84.

Welcome!

Jun 1, 2012

It is with real pleasure that I join the Pharmaceutical Technology Europe (PTE) team.

Looking Forward to Meeting You in Frankfurt!

May 31, 2012

ACHEMA is just around the corner and there is a high sense of expectation from attendees and exhibitors alike?and the Pharmaceutical Technology Europe team! Our new Editor, Dr Jo Watts, is looking forward to meeting you all at the show in Hall 31, Stand J25.

USP Further Strengthens Heparin Standards

May 23, 2012

The US Pharmacopeia has issued a third round of improvements to its blood thinner standard.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here